These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 23770332)

  • 21. Feasibility of jet injector use during inactivated poliovirus vaccine house-to-house vaccination campaigns.
    Farag NH; Mansour Z; Torossian L; Said R; Snider CJ; Ehrhardt D
    Vaccine; 2018 Aug; 36(32 Pt B):4935-4938. PubMed ID: 29980387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
    Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
    Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.
    Anand A; Molodecky NA; Pallansch MA; Sutter RW
    Vaccine; 2017 May; 35(22):2993-2998. PubMed ID: 28434691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability.
    Daly C; Molodecky NA; Sreevatsava M; Belayneh AD; Chandio SA; Partridge J; Shaikh A; Laghari M; Agbor J; Safdar RM; Bullo UF; Malik SM; Mahamud A
    Vaccine; 2020 Feb; 38(8):1893-1898. PubMed ID: 31983581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intradermal fractional dose inactivated polio vaccine: a review of the literature.
    Nelson KS; Janssen JM; Troy SB; Maldonado Y
    Vaccine; 2012 Jan; 30(2):121-5. PubMed ID: 22100886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
    Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
    Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
    Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia.
    Bashorun AO; Badjie Hydara M; Adigweme I; Umesi A; Danso B; Johnson N; Sambou NA; Fofana S; Kanu FJ; Jeyaseelan V; Verma H; Weldon WC; Oberste MS; Sutter RW; Jeffries D; Wathuo M; Mach O; Clarke E
    Lancet Glob Health; 2022 Feb; 10(2):e257-e268. PubMed ID: 34951974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.
    Kouiavskaia D; Mirochnitchenko O; Dragunsky E; Kochba E; Levin Y; Troy S; Chumakov K
    J Infect Dis; 2015 May; 211(9):1447-50. PubMed ID: 25391313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
    Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
    Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.
    Resik S; Tejeda A; Diaz M; Okayasu H; Sein C; Molodecky NA; Fonseca M; Alemany N; Garcia G; Hung LH; Martinez Y; Sutter RW
    J Infect Dis; 2017 Jan; 215(2):175-182. PubMed ID: 28073858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.
    Nelson EA; Lam HS; Choi KC; Ho WC; Fung LW; Cheng FW; Sung RY; Royals M; Chan PK
    Vaccine; 2013 Jul; 31(34):3452-60. PubMed ID: 23770335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats.
    Ma Y; Ying Z; Li J; Gu Q; Wang X; Cai L; Shi L; Sun M
    Biologicals; 2022 Jan; 75():3-11. PubMed ID: 35058137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar protective immunity to intramuscular inoculation of a full dose of an Al(OH)
    Li M; Duan Y; Yang X; Yang Q; Pang B; Wang Y; Ren T; Wang X; Zhao Z; Liu S
    Vaccine; 2017 Jun; 35(30):3709-3717. PubMed ID: 28576572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S; Friedland LR; Schuind A; Howe B;
    Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization.
    Okayasu H; Sein C; Chang Blanc D; Gonzalez AR; Zehrung D; Jarrahian C; Macklin G; Sutter RW
    J Infect Dis; 2017 Jul; 216(suppl_1):S161-S167. PubMed ID: 28838185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
    Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
    Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.